Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Clinical trial NCT02753595 · TERMINATED
Trial details
- NCT number
- NCT02753595
- Sponsor
- Eisai Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-13
- Primary completion
- 2019-08-16
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.